Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
57
FATE Quote, Financials, Valuation and Earnings
Last price:
$1.37
Seasonality move
:
3.56%
Day range:
$1.33 - $1.40
52-week range:
$0.66 - $1.94
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
22.73x
P/B ratio:
0.68x
Volume:
1.3M
Avg. volume:
1.7M
1-year change:
-10.46%
Market cap:
$158M
Revenue:
$13.6M
EPS (TTM):
-$1.32
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
FATE
Fate Therapeutics, Inc.
|
$1.2M | -$0.27 | -40.38% | -12.79% | $4.94 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.5M | $0.14 | 13.44% | 28.72% | $31.21 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.86% | -58.59% | $457.00 |
|
ARDX
Ardelyx, Inc.
|
$118M | $0.01 | 44.63% | -97.68% | $14.70 |
|
MNKD
MannKind Corp.
|
$99.9M | $0.03 | 30.05% | 17.65% | $9.61 |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
$3.2B | $5.15 | 11.14% | 76.99% | $530.07 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
FATE
Fate Therapeutics, Inc.
|
$1.37 | $4.94 | $158M | -- | $0.00 | 0% | 22.73x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$23.20 | $31.21 | $3.9B | 14.93x | $0.00 | 0% | 3.73x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$332.68 | $457.00 | $44.1B | 147.39x | $0.00 | 0% | 11.96x |
|
ARDX
Ardelyx, Inc.
|
$6.72 | $14.70 | $1.6B | -- | $0.00 | 0% | 4.07x |
|
MNKD
MannKind Corp.
|
$5.44 | $9.61 | $1.7B | 57.75x | $0.00 | 0% | 5.35x |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
$470.31 | $530.07 | $119.5B | 30.67x | $0.00 | 0% | 10.05x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
FATE
Fate Therapeutics, Inc.
|
25.29% | 1.380 | 54.53% | 7.69x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.064 | 5.64% | 2.51x |
|
ARDX
Ardelyx, Inc.
|
57.37% | -0.695 | 15.51% | 3.83x |
|
MNKD
MannKind Corp.
|
124.56% | -0.068 | 13.7% | 2.54x |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
9.84% | -0.890 | 1.77% | 2.24x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
FATE
Fate Therapeutics, Inc.
|
-$1.5M | -$34.7M | -41.23% | -53.28% | -1995.12% | -$26.6M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
ARDX
Ardelyx, Inc.
|
$105.4M | $4.7M | -17.69% | -36.67% | 4.23% | $209K |
|
MNKD
MannKind Corp.
|
$61.9M | $18.8M | 24.75% | -- | 22.86% | $22.4M |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
$2.8B | $1.3B | 20.84% | 22.97% | 40.3% | $348.6M |
Fate Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns FATE or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -1852.38% compared to Fate Therapeutics, Inc.'s net margin of 25.76%. Fate Therapeutics, Inc.'s return on equity of -53.28% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital FATEFate Therapeutics, Inc.-85.35% -$0.27 $313.3M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About FATE or ACAD?
Fate Therapeutics, Inc. has a consensus price target of $4.94, signalling upside risk potential of 260.91%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.21 which suggests that it could grow by 34.53%. Given that Fate Therapeutics, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Fate Therapeutics, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FATEFate Therapeutics, Inc.5 6 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is FATE or ACAD More Risky?
Fate Therapeutics, Inc. has a beta of 2.246, which suggesting that the stock is 124.561% more volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock FATE or ACAD?
Fate Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fate Therapeutics, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FATE or ACAD?
Fate Therapeutics, Inc. quarterly revenues are $1.7M, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Fate Therapeutics, Inc.'s net income of -$32.3M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Fate Therapeutics, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 14.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fate Therapeutics, Inc. is 22.73x versus 3.73x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FATEFate Therapeutics, Inc.22.73x -- $1.7M -$32.3M ACADACADIA Pharmaceuticals, Inc.3.73x 14.93x $278.6M $71.8M
-
Which has Higher Returns FATE or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -1852.38% compared to Fate Therapeutics, Inc.'s net margin of 16.99%. Fate Therapeutics, Inc.'s return on equity of -53.28% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital FATEFate Therapeutics, Inc.-85.35% -$0.27 $313.3M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About FATE or ALNY?
Fate Therapeutics, Inc. has a consensus price target of $4.94, signalling upside risk potential of 260.91%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 37.37%. Given that Fate Therapeutics, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Fate Therapeutics, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FATEFate Therapeutics, Inc.5 6 0 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is FATE or ALNY More Risky?
Fate Therapeutics, Inc. has a beta of 2.246, which suggesting that the stock is 124.561% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock FATE or ALNY?
Fate Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fate Therapeutics, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FATE or ALNY?
Fate Therapeutics, Inc. quarterly revenues are $1.7M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Fate Therapeutics, Inc.'s net income of -$32.3M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Fate Therapeutics, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 147.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fate Therapeutics, Inc. is 22.73x versus 11.96x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FATEFate Therapeutics, Inc.22.73x -- $1.7M -$32.3M ALNYAlnylam Pharmaceuticals, Inc.11.96x 147.39x $1.1B $186.4M
-
Which has Higher Returns FATE or ARDX?
Ardelyx, Inc. has a net margin of -1852.38% compared to Fate Therapeutics, Inc.'s net margin of -0.88%. Fate Therapeutics, Inc.'s return on equity of -53.28% beat Ardelyx, Inc.'s return on equity of -36.67%.
Company Gross Margin Earnings Per Share Invested Capital FATEFate Therapeutics, Inc.-85.35% -$0.27 $313.3M ARDXArdelyx, Inc.95.57% -$0.00 $361.9M -
What do Analysts Say About FATE or ARDX?
Fate Therapeutics, Inc. has a consensus price target of $4.94, signalling upside risk potential of 260.91%. On the other hand Ardelyx, Inc. has an analysts' consensus of $14.70 which suggests that it could grow by 118.75%. Given that Fate Therapeutics, Inc. has higher upside potential than Ardelyx, Inc., analysts believe Fate Therapeutics, Inc. is more attractive than Ardelyx, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FATEFate Therapeutics, Inc.5 6 0 ARDXArdelyx, Inc.10 0 0 -
Is FATE or ARDX More Risky?
Fate Therapeutics, Inc. has a beta of 2.246, which suggesting that the stock is 124.561% more volatile than S&P 500. In comparison Ardelyx, Inc. has a beta of 0.570, suggesting its less volatile than the S&P 500 by 43.011%.
-
Which is a Better Dividend Stock FATE or ARDX?
Fate Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ardelyx, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fate Therapeutics, Inc. pays -- of its earnings as a dividend. Ardelyx, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FATE or ARDX?
Fate Therapeutics, Inc. quarterly revenues are $1.7M, which are smaller than Ardelyx, Inc. quarterly revenues of $110.3M. Fate Therapeutics, Inc.'s net income of -$32.3M is lower than Ardelyx, Inc.'s net income of -$969K. Notably, Fate Therapeutics, Inc.'s price-to-earnings ratio is -- while Ardelyx, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fate Therapeutics, Inc. is 22.73x versus 4.07x for Ardelyx, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FATEFate Therapeutics, Inc.22.73x -- $1.7M -$32.3M ARDXArdelyx, Inc.4.07x -- $110.3M -$969K
-
Which has Higher Returns FATE or MNKD?
MannKind Corp. has a net margin of -1852.38% compared to Fate Therapeutics, Inc.'s net margin of 9.72%. Fate Therapeutics, Inc.'s return on equity of -53.28% beat MannKind Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital FATEFate Therapeutics, Inc.-85.35% -$0.27 $313.3M MNKDMannKind Corp.75.4% $0.03 $181.4M -
What do Analysts Say About FATE or MNKD?
Fate Therapeutics, Inc. has a consensus price target of $4.94, signalling upside risk potential of 260.91%. On the other hand MannKind Corp. has an analysts' consensus of $9.61 which suggests that it could grow by 76.68%. Given that Fate Therapeutics, Inc. has higher upside potential than MannKind Corp., analysts believe Fate Therapeutics, Inc. is more attractive than MannKind Corp..
Company Buy Ratings Hold Ratings Sell Ratings FATEFate Therapeutics, Inc.5 6 0 MNKDMannKind Corp.8 0 0 -
Is FATE or MNKD More Risky?
Fate Therapeutics, Inc. has a beta of 2.246, which suggesting that the stock is 124.561% more volatile than S&P 500. In comparison MannKind Corp. has a beta of 0.839, suggesting its less volatile than the S&P 500 by 16.131%.
-
Which is a Better Dividend Stock FATE or MNKD?
Fate Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fate Therapeutics, Inc. pays -- of its earnings as a dividend. MannKind Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FATE or MNKD?
Fate Therapeutics, Inc. quarterly revenues are $1.7M, which are smaller than MannKind Corp. quarterly revenues of $82.1M. Fate Therapeutics, Inc.'s net income of -$32.3M is lower than MannKind Corp.'s net income of $8M. Notably, Fate Therapeutics, Inc.'s price-to-earnings ratio is -- while MannKind Corp.'s PE ratio is 57.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fate Therapeutics, Inc. is 22.73x versus 5.35x for MannKind Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FATEFate Therapeutics, Inc.22.73x -- $1.7M -$32.3M MNKDMannKind Corp.5.35x 57.75x $82.1M $8M
-
Which has Higher Returns FATE or VRTX?
Vertex Pharmaceuticals, Inc. has a net margin of -1852.38% compared to Fate Therapeutics, Inc.'s net margin of 36.91%. Fate Therapeutics, Inc.'s return on equity of -53.28% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.97%.
Company Gross Margin Earnings Per Share Invested Capital FATEFate Therapeutics, Inc.-85.35% -$0.27 $313.3M VRTXVertex Pharmaceuticals, Inc.85.56% $4.65 $20.7B -
What do Analysts Say About FATE or VRTX?
Fate Therapeutics, Inc. has a consensus price target of $4.94, signalling upside risk potential of 260.91%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $530.07 which suggests that it could grow by 12.71%. Given that Fate Therapeutics, Inc. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Fate Therapeutics, Inc. is more attractive than Vertex Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FATEFate Therapeutics, Inc.5 6 0 VRTXVertex Pharmaceuticals, Inc.21 5 1 -
Is FATE or VRTX More Risky?
Fate Therapeutics, Inc. has a beta of 2.246, which suggesting that the stock is 124.561% more volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.303, suggesting its less volatile than the S&P 500 by 69.725%.
-
Which is a Better Dividend Stock FATE or VRTX?
Fate Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fate Therapeutics, Inc. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FATE or VRTX?
Fate Therapeutics, Inc. quarterly revenues are $1.7M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.2B. Fate Therapeutics, Inc.'s net income of -$32.3M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.2B. Notably, Fate Therapeutics, Inc.'s price-to-earnings ratio is -- while Vertex Pharmaceuticals, Inc.'s PE ratio is 30.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fate Therapeutics, Inc. is 22.73x versus 10.05x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FATEFate Therapeutics, Inc.22.73x -- $1.7M -$32.3M VRTXVertex Pharmaceuticals, Inc.10.05x 30.67x $3.2B $1.2B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
73
HYMC alert for Feb 19
Hycroft Mining Holding Corp. [HYMC] is up 21.1% over the past day.
Buy
90
TCMD alert for Feb 19
Tactile Systems Technology, Inc. [TCMD] is up 17.83% over the past day.
Buy
57
GLBE alert for Feb 19
Global-e Online Ltd. [GLBE] is up 17.31% over the past day.
